Quercetin
Of 2,238 on-market quercetin products in the January 2026 DSLD dump, the median declared dose is 100 mg, and 99.0% list Quercetin Dihydrate as the primary form.
Form share
Of 2,214 products with an identifiable primary form, here is the share held by each form of Quercetin on the market today.
| Form | Quality tier | n | Share |
|---|---|---|---|
| Quercetin Dihydrate | Tier 2 | 2,191 | 99.0% |
| Sophora japonica / Dimorphandra mollis extract (source-plant labeling) | Unrated | 23 | 1.0% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mg), among 1,505 products with a disclosed amount.
- 13.2% of products fall below the fairy-dust threshold (20 mg, 20% of the studied low dose).
- 31.4% of products don't disclose an amount because Quercetin is declared inside a proprietary blend.
By dosage form
By target group
Top brands
Forms explained
Standard crystalline form used in most human RCTs including the BP meta-analysis, but has documented poor intrinsic solubility/absorption (<5% oral bioavailability in bioavailability reviews).
Source: Serban MC et al. 2016, J Am Heart Assoc 5(7):e002713, PMID 27405810
Directly compared head-to-head against standard quercetin in human PK trials and shown to substantially increase plasma exposure (~20-fold higher in one 12-subject crossover) at equal or lower dose.
Source: Riva A et al. 2019, Eur J Drug Metab Pharmacokinet 44(2):169-177, PMID 30328058
Raw-material source descriptors, not a functionally distinct delivery form -- insufficient evidence they differ from generic quercetin dihydrate/aglycone once standardized.
Source: uncertain -- needs review
Reference values
- RDA (adult): not established — Plant-derived flavonoid, not an essential nutrient; no DRI exists.
- Tolerable Upper Intake Level (adult): not established — Not established -- no IOM/NASEM UL exists. Trials up to ~1000mg/day for weeks have not reported serious adverse effects, but this is not a formal UL.
- Studied clinical dose range: 100–1000 mg
- Serban MC et al. 2016, J Am Heart Assoc 5(7):e002713, PMID 27405810 -- meta-analysis, pooled RCTs (100-1000mg/day); significant blood-pressure reduction, significant only at doses >=500mg/day.